{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:12:59Z","timestamp":1780567979220,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucocorticoid-induced osteoporosis and vertebral fracture are common complications in patients on glucocorticoid treatment for rheumatological diseases. The present study aimed to identify the risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 225 Japanese women with glucocorticoid-induced osteoporosis and 72 patients with postmenopausal osteoporosis. All participants were treated with bisphosphonate or denosumab for osteoporosis with active form of vitamin D for at least 3\u2009years. The differences of clinical parameters, including age, disease duration, body mass index (BMI), bone mineral density (BMD), and the dose and treatment duration of glucocorticoid were assessed between patients with and without vertebral fracture. Multivariate logistic regression analysis was also performed to evaluate the association of vertebral fracture with clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The significant differences related to age, BMD of the hip, disease duration, glucocorticoid treatment duration between patients with and without vertebral fractures were demonstrated. The present study indicated that disease duration, BMI, and the total hip BMD were independent risk factors for vertebral fractures in patients with glucocorticoid-induced osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prolonged disease duration, low BMI, and low total hip BMD could be risk factors of vertebral fracture in patients on glucocorticoid treatment for rheumatological diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13018-020-01813-4","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T09:05:10Z","timestamp":1596013510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-4690","authenticated-orcid":false,"given":"Yu","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Izumiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Itoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"issue":"2","key":"1813_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr.21796","volume":"65","author":"RA Overman","year":"2013","unstructured":"Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294\u20138.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"1813_CR2","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00198-015-3455-9","volume":"27","author":"MA Amiche","year":"2016","unstructured":"Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Levesque LE, Adachi JD, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709\u201318.","journal-title":"Osteoporos Int."},{"issue":"9","key":"1813_CR3","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257\u201376.","journal-title":"Osteoporos Int."},{"issue":"11","key":"1813_CR4","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224\u20139.","journal-title":"Arthritis Rheum."},{"issue":"10","key":"1813_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777\u201387.","journal-title":"Osteoporos Int."},{"key":"1813_CR6","doi-asserted-by":"crossref","first-page":"1759720X1987646","DOI":"10.1177\/1759720X19876468","volume":"11","author":"G Adami","year":"2019","unstructured":"Adami G, Rahn EJ, Saag KG. Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice. Ther Adv Musculoskelet Dis. 2019;11:1759720X19876468.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"1813_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/art.22294","volume":"56","author":"F De Vries","year":"2007","unstructured":"De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208\u201314.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"1813_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15(4):323\u20138.","journal-title":"Osteoporos Int."},{"issue":"9","key":"1813_CR9","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/s00198-013-2352-3","volume":"24","author":"SR Majumdar","year":"2013","unstructured":"Majumdar SR, Morin SN, Lix LM, Leslie WD. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int. 2013;24(9):2493\u20138.","journal-title":"Osteoporos Int."},{"issue":"12","key":"1813_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383\u20139.","journal-title":"Rheumatology (Oxford)."},{"issue":"8","key":"1813_CR11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3899\/jrheum.081337","volume":"36","author":"EK Li","year":"2009","unstructured":"Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36(8):1646\u201352.","journal-title":"J Rheumatol."},{"issue":"7","key":"1813_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/rheumatology\/kem105","volume":"46","author":"K Almehed","year":"2007","unstructured":"Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford). 2007;46(7):1185\u201390.","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"1813_CR13","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.22691","volume":"56","author":"S Compeyrot-Lacassagne","year":"2007","unstructured":"Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 2007;56(6):1966\u201373.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"1813_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292\u20139.","journal-title":"N Engl J Med."},{"issue":"6","key":"1813_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15(6):1006\u201313.","journal-title":"J Bone Miner Res."},{"issue":"9671","key":"1813_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253\u201363.","journal-title":"Lancet."},{"issue":"1","key":"1813_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202\u201311.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"1813_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277\u201385.","journal-title":"Calcif Tissue Int."},{"issue":"7","key":"1813_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019;71(7):1174\u201384.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"1813_CR20","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346\u201355.","journal-title":"Arthritis Rheum."},{"issue":"20","key":"1813_CR21","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028\u201339.","journal-title":"N Engl J Med."},{"issue":"22","key":"1813_CR22","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.2169\/internalmedicine.50.5266","volume":"50","author":"D Kirigaya","year":"2011","unstructured":"Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T. Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. Intern Med. 2011;50(22):2793\u2013800.","journal-title":"Intern Med."},{"issue":"1","key":"1813_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jocd.2018.03.009","volume":"22","author":"M Carter","year":"2019","unstructured":"Carter M. Prevention of glucocorticoid-induced osteoporosis: clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. J Clin Densitom. 2019;22(1):25\u201330.","journal-title":"J Clin Densitom."},{"issue":"4","key":"1813_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32(4):337\u201350.","journal-title":"J Bone Miner Metab."},{"issue":"3","key":"1813_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, et al. Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab. 2013;31(3):247\u201357.","journal-title":"J Bone Miner Metab."},{"issue":"9","key":"1813_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00198-004-1600-y","volume":"15","author":"S Muraki","year":"2004","unstructured":"Muraki S, Yamamoto S, Ishibashi H, Horiuchi T, Hosoi T, Orimo H, et al. Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women. Osteoporos Int. 2004;15(9):724\u20138.","journal-title":"Osteoporos Int."},{"key":"1813_CR27","doi-asserted-by":"publisher","first-page":"233372142091477","DOI":"10.1177\/2333721420914771","volume":"6","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Takada T, Narushima T, Tsukada A, Ishikawa E, Matsumura A. Correlation between bone density and lumbar compression fractures. Gerontol Geriatr Med. 2020;6:2333721420914771.","journal-title":"Gerontol Geriatr Med."},{"issue":"1","key":"1813_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jor.2018.01.029","volume":"15","author":"Y Mori","year":"2018","unstructured":"Mori Y, Baba K, Kogure A, Izumiyama T, Matsuda M, Mori N, et al. Assessment of the risk of low bone mineral density in premenopausal Japanese female patients with systemic lupus erythematosus. J Orthop. 2018;15(1):89\u201393.","journal-title":"J Orthop."},{"issue":"1","key":"1813_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00774-015-0716-9","volume":"35","author":"Y Mori","year":"2017","unstructured":"Mori Y, Kuwahara Y, Chiba S, Kogre A, Baba K, Kamimura M, et al. Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment. J Bone Miner Metab. 2017;35(1):52\u20137.","journal-title":"J Bone Miner Metab."},{"issue":"2","key":"1813_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253\u20139.","journal-title":"Bone."},{"issue":"4","key":"1813_CR31","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00198-013-2587-z","volume":"25","author":"IE Bultink","year":"2014","unstructured":"Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int. 2014;25(4):1275\u201383.","journal-title":"Osteoporos Int."},{"issue":"11","key":"1813_CR32","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","volume":"27","author":"A Balasubramanian","year":"2016","unstructured":"Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O\u2019Malley CD, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239\u201349.","journal-title":"Osteoporos Int."}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-020-01813-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-020-01813-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-020-01813-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T19:25:42Z","timestamp":1627500342000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-020-01813-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s13018-020-01813-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-30671\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30671\/v2","asserted-by":"object"}]},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Tohoku University Hospital.Informed consent was obtained from all patients in accordance with the Declaration of Helsinki before participating in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}